Folic Acid Metabolism Inhibitors

Folate Analog Metabolic Inhibitor

Arthritis, Juvenile

Arthritis, Rheumatoid

Breast Neoplasms

Choriocarcinoma

Crohn Disease

Esophageal Neoplasms

Hydatidiform Mole

Leukemia

Lung Neoplasms

Mycosis Fungoides

Psoriasis

Osteosarcoma

Stomach Neoplasms

Testicular Neoplasms

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-10"></a><h1>11 DESCRIPTION</h1>Rasuvo contains methotrexate, a folate analog metabolic inhibitor.Chemically, methotrexate is [N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-Lglutamic acid. The structural formula is:<img alt="Chemical Structure" src="rasuvo-01.jpg"/>C20H22N8O5      M.W.= 454.45Rasuvo contains methotrexate in a sterile, preservative-free, non-pyrogenic solution for a single subcutaneous injection. Rasuvo is an isotonic, clear, yellow to brown solution.Rasuvo contains the following inactive ingredients: sodium chloride 0.4% w/v; water for injections, sodium hydroxide and, if necessary, hydrochloric acid are added to adjust the pH to approximately 8.5.</section>

Rasuvo

0.4 ML methotrexate 50 MG/ML Auto-Injector

0.2 ML methotrexate 50 MG/ML Auto-Injector

0.2 ML methotrexate 50 MG/ML Auto-Injector [Rasuvo]

0.25 ML methotrexate 50 MG/ML Auto-Injector

0.25 ML methotrexate 50 MG/ML Auto-Injector [Rasuvo]

0.3 ML methotrexate 50 MG/ML Auto-Injector

0.3 ML methotrexate 50 MG/ML Auto-Injector [Rasuvo]

0.35 ML methotrexate 50 MG/ML Auto-Injector

0.35 ML methotrexate 50 MG/ML Auto-Injector [Rasuvo]

0.4 ML methotrexate 50 MG/ML Auto-Injector [Rasuvo]

0.45 ML methotrexate 50 MG/ML Auto-Injector

0.45 ML methotrexate 50 MG/ML Auto-Injector [Rasuvo]

0.5 ML methotrexate 50 MG/ML Auto-Injector

0.5 ML methotrexate 50 MG/ML Auto-Injector [Rasuvo]

0.6 ML methotrexate 50 MG/ML Auto-Injector

0.6 ML methotrexate 50 MG/ML Auto-Injector [Rasuvo]

0.15 ML methotrexate 50 MG/ML Auto-Injector

0.15 ML methotrexate 50 MG/ML Auto-Injector [Rasuvo]

methotrexate

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event

Prescribing Information

Medication Guide 

Pharmacy List 

Coverage Authorization Request 

Coverage Authorization Appeal 

Letter of Medical Necessity 

Formulary Tier Exception Letter 

Dose Modification Request Letter 

Benefits Investigation Form 

Enroll in Patient Savings Program 

Patient Brochure 

RA Pain Journal 

About Rasuvo: RA 

About Rasuvo: pJIA

Sharps Container 

FAQs: RA, pJIA & Psoriasis 

Instructions For Use: Plaque Psoriasis 

Instructions For Use: Rheumatoid Arthritis 

Instructions For Use: Polyarticular Juvenile Idiopathic Arthritis (pJIA)

Side Effects: RA 